LABORATORY CORPORATION OF AMERICA HOLDINGS

Laboratory Corporation of America Holdings

Equities

LH

US50540R4092

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 04:00:02 2024-04-23 pm EDT			5-day change	1st Jan Change
208 ^USD	+2.41%		+2.99%	-8.50%

Apr. 15	Labcorp Introduces Test for Early Detection of Neurodegenerative Diseases	MT
Apr. 15	Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw	CI

Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021.

August 01, 2022 at 02:31 pm EDT

From April 1, 2022 to June 30, 2022, the company has repurchased 1,900,000 shares, representing 2.05% for $404.73 million. With this, the company has completed the repurchase of 5,235,604 shares, representing 5.55% for $1,404.73 million under the buyback announced on December 9, 2021.

Latest news about Laboratory Corporation of America Holdings

Labcorp Introduces Test for Early Detection of Neurodegenerative Diseases	Apr. 15	MT
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw	Apr. 15	CI
Labcorp Keeps Quarterly Dividend at $0.72 Per Share, Payable June 12 to Stockholders of Record May 28	Apr. 11	MT
Labcorp Declares Quarterly Dividend, Payable on June 12, 2024	Apr. 11	CI
Sector Update: Health Care Stocks Slump Wednesday Afternoon	Apr. 10	MT
Labcorp Says US FDA Granted Emergency Use Authorization for Mpox Home Collection Kit	Apr. 10	MT
Labcorp Gets Emergency Authorization from FDA for Home Kit to Detect Monkeypox	Apr. 10	DJ
Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit	Apr. 10	CI
Laboratory Corp of America Expands Precision Oncology Portfolio	Apr. 08	MT
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs	Apr. 08	CI
Labcorp Launches Labcorp Plasma Detect? Extending Leadership into Molecular Residual Disease Clinical Research	Apr. 05	CI
Laboratory Corporation Receives a Shareholder Proposal from People for the Ethical Treatment of Animals	Apr. 04	CI
Laboratory Corporation Receives a Shareholder Proposal from Tara Health Foundation	Apr. 04	CI
Laboratory Corporation Receives a Shareholder Proposal from John Chevedden	Apr. 04	CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $760,515, According to a Recent SEC Filing	Apr. 03	MT
Laboratory Corp Of America Holdings Insider Sold Shares Worth $1,407,387, According to a Recent SEC Filing	Apr. 03	MT
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research	Apr. 02	CI
Labcorp Expands Investment, Collaboration Pact with Xcell Biosciences	Apr. 01	MT
Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration with Labcorp	Apr. 01	CI
Prelude Network Announces Expansion of Partnership with Labcorp to Serve as Its Preferred Genetic Carrier Screening Lab	Mar. 29	CI
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	Mar. 28	MT
Laboratory Corporation of America Holdings (NYSE:LH) entered into an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.	Mar. 27	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Argus Upgrades Laboratory Corp of America Holdings to Buy From Hold, Price Target is $250	Mar. 25	MT
Laboratory Corp of America Launches PTau217 Diagnostic Test for Alzheimer's Disease	Mar. 20	MT

Chart Laboratory Corporation of America Holdings

Duration

Period

Chart Laboratory Corporation of America Holdings

More charts

Company Profile

Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows: - clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services; - development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies. Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).

Sector

Healthcare Facilities & Services

Calendar

2024-04-24 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Laboratory Corporation of America Holdings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

203.1 USD

Average target price

243.8 USD

Spread / Average Target

+20.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.50%	17.08B
CVS HEALTH CORPORATION	-13.25%	87.77B
HCA HEALTHCARE, INC.	+18.01%	82.08B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.97%	30.03B
FRESENIUS SE & CO. KGAA	-1.46%	16.41B
EUROFINS SCIENTIFIC SE	+4.44%	12.37B
FRESENIUS MEDICAL CARE AG	+5.11%	12.17B
PURE HEALTH HOLDING	-31.05%	11.89B
DAVITA INC.	+27.83%	11.62B
UNIVERSAL HEALTH SERVICES, INC.	+8.18%	10.85B

Other Healthcare Facilities & Services